All News
EULAR 2024 - Day 1 Report
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs
>1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.
Dr. John Cush RheumNow ( View Tweet)
Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively?
VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed.
I’ll admit, I’m still not game!
#EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov
Links:
David Liew drdavidliew ( View Tweet)
How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis?
Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed.
#EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC
Links:
David Liew drdavidliew ( View Tweet)
OP0131 on occurrence & predictors of #DMARD treatment failure in #RA
8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure
In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs
Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA
📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA
💊MTX after start of advanced therapy protective of D2T RA
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzumab led to profound circulatory depletion in #lupus nephritis & those w sustained depletion had better complete renal response than those who didn’t @RheumNow https://t.co/2KTZBR2njk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Poster tours at #EULAR2024.
A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
Dr. Antoni Chan synovialjoints ( View Tweet)
Who needs intensive therapy in #lupus
Intensive Rx in #SLE from 2 inception cohorts in Leeds
Either #Cyclo or #biologics
⬆️
If low complement
Within 2 yrs after #dx
#SLEDAI >9
AntiRo+
OP0187
#EULAR2024 @RheumNow @eular_org https://t.co/oKhwMmHhSs
Links:
Janet Pope Janetbirdope ( View Tweet)
Top 3 messages
Re
#JAKi #safety
Shared decision w benefit/risk info
Some #CV risks are more Impt than others- stratify your pt into risk categories
#Smoking is a big risk for #MACE &
#malignancy-So work on facilitating
Smoking #cessation
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
3 facts in #lupus to make you think 🤔
💧biomarkers in #SLE blood & #urine May predict #activity
OP0255
#Membranous #nephritis is serious in SLE @ZahiTouma POS0732
#prednisone dose irrelevant for #damage if in LLDAS -no diff between 7.5mg vs 5mg OP0124
#EULAR2024 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
#Hope for patients with #active #SLE
The next hurdle is getting through
▶️Phase3 #RCTs
And
▶️Obtaining drug reimbursement so patients can get access to effective
#lupus #Rx
#EULAR2024
@RheumNow @eular_org https://t.co/sGzQXO4A2r
Janet Pope Janetbirdope ( View Tweet)
OP0072 @RheumNow #EULAR2024
Effects of #Upadacitinib or #Adalimumab on pain in #RA
SELECT-COMPARE Phase 3 study
UPA & ADA led to improvements in pain vs PBO
PtGA & TJC28 pain improvement similar between UPA & ADA
➡️ UPA may be more effective in control of pain than ADA in RA
Mrinalini Dey DrMiniDey ( View Tweet)
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Dr. Antoni Chan synovialjoints ( View Tweet)
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts
▶️ #Shingrix works
👍Pts followed to 60 months
#EULAR2024
@eular_org @RheumNow
#OP0020 https://t.co/8ORC3Nd2FK
Janet Pope Janetbirdope ( View Tweet)